Thymoma
61
9
15
24
Key Insights
Highlights
Success Rate
80% trial completion
Published Results
11 trials with published results (18%)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 49/100
9.8%
6 terminated out of 61 trials
80.0%
-6.6% vs benchmark
3%
2 trials in Phase 3/4
46%
11 of 24 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 24 completed trials
Clinical Trials (61)
A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy
Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
Incidence and Predictors of Early Clinical Relapse Within Six Months After Thymectomy in Patients With Myasthenia Gravis
Intravenous Palifosfamide-tris in Combination With Etoposide and Carboplatin in Patients With Malignancies
An Investigational Scan (MRI) in Imaging Patients With Newly-Diagnosed or Recurrent Thymoma
SP Thoracic IDE Study
A Phase II Trial of Sacituzumab Govitecan in Patients With Advanced Thymic Epithelial Tumors
Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma
Hypofractionated Adjuvant Radiotherapy for Thymic Epithelial Tumors
Depressive Tendency and Counseling Outcomes in Thymoma-Associated MG
Thymic Disease, Autoimmunity, and Neuromuscular Junction Integrity in Myasthenia Gravis
Adjuvant Radiotherapy for Stage II/III Thymoma After Complete Resection
177Lu-DOTA-TATE and Olaparib in Somatostatin Receptor Positive Tumours
Electrocautery Resection Combined With HITHOC for Thymic Epithelial Tumors With Pleural Metastasis
Molecular Analysis of Thoracic Malignancies
Tislelizumab Combined With Anlotinib as Second-line Therapy in Thymoma and Thymic Carcinoma
IL-8+ naïve T Cells as a Biomarker for Thymoma Identification
Glucocorticoids Combined With Concurrent Chemoradiotherapy for Unresectable Thymoma
Hypofractionated Radiotherapy for Thymic Epithelial Tumors
Sunitinib for Advanced Thymus Cancer Following Earlier Treatment